🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "significant breakthrough" in the effort against increasingly resistant strains of the bacteria, according to researchers.

A Worldwide Health Concern

The sexually transmitted infection are escalating worldwide, with data suggesting over 82 million infections each year. Notably increased rates are seen in Africa and countries within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an important and timely step in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices currently available.”

Medical experts are increasingly worried about the surge in drug-resistant strains. The WHO has designated it as a "critical concern". Ongoing monitoring found that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Treatment Options Receive Approval

Zoliflodacin, also known as a brand name, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the development of resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, gained clearance in concurrent days. This medication, which is also used to treat UTIs, was demonstrated in studies to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment stemmed from a innovative non-profit model for drug creation. The charitable organization GARDP collaborated with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a major breakthrough in the treatment of superbug gonorrhoea, which previously has been outpacing antibiotic development.”

Research Study Outcomes and Global Access

According to results released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which uses a dual-drug approach. The research enrolled nearly 1,000 participants from various regions including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the ability to license and sell the drug in many developing nations.

Clinicians directly involved have voiced positive views. Access to a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is deemed essential to reduce the burden of the disease for patients and to prevent the spread of untreatable gonorrhoea around the world.